echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Three mainstream ED-class drugs combined to take more than 3.3 billion! The rise of domestic brands.

    Three mainstream ED-class drugs combined to take more than 3.3 billion! The rise of domestic brands.

    • Last Update: 2020-07-29
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Pharmaceutical Network July 29th, NMPA official website released the latest information, Collum Pharmaceuticals' first ED-type drug Vandina is not approved for listing, becoming the first imitation in China, and as reviewedAccording to Mione.com, the national sales of the three major ED-type drugs in 2019 have exceeded 3.3 billion, of which hedaraf, Valdina non-growth rate of more than 10%, Sidafi is still the main market, Baiyunshan for the first time overtook Pfizer as the retail market TOP1 brandDomestic ED-type drug research and development activity is very high, 2020 24 new products (products and enterprises) are expected to be approved, a new generation of ED-class drug Avananon film of the first imitation of the competition is worth looking forward toCollum took the ED-type star drug, with Bayer a hit-and-run Figure 1: Columvandinafi's approval situation Source: NMPA Official Web Chart 2: Original Bayer's latest winning bid Source: Minne net one key search hydrochloric acid defied na non-chip original research Developed jointly by Bayer and GSK, it was first approved in the European Union in 2003, subsequently approved for listing in the United States and Japan, and was approved for import in China in 2004, with only Bayer receiving import approval at present, the latest winning bid for the product in Jiangsu Province is 95.17 yuan per piece (200mg)Collum Pharmaceuticals' application for a generic 4 generic version of hydrochloric acid was filed by CDE in June 2018 and was given priority review in September of the same year on the grounds of "drug production application simply one year prior to the expiration of the patent"So far, only Collum declared four types of imitation listing, Qilu's six types of imitation listing application in 2016 after the approval of clinical no further information, Yangzijiang in July 2020 to carry out BE, the latest status is "in progress has not yet been recruited." In this way, Colum is the first and then no one, in a considerable period of time can be confident to plan the market channel layoutIn May this year, Curran's first urinary system drug dapostine tablets were approved for the market, according to relevant sources, the product in public hospitals and retail markets have a good performance, the future layout of hydrochloric acid defisite will also refer to the previous experience and adjustDomestic brands have a price advantage, and a fierce battle between Curran and Bayer is inevitableThree mainstream ED-type drugs to the market of 3.3 billion, retail pharmacies into the main battleground chart 3: 2019 three major mainstream ED drugs national sales source: Minet database ED first-line treatment therapy is mainly oral drug treatment, clinically commonly used drugs are type 5 phosphate diesterase inhibitors (PDE5), the current listed PDE5 inhibitors are sildenafi, tadalafi, valina, etcAccording to The Inner Net data, in China's urban public hospitals, county-level public hospitals, urban community centers, township hospitals (referred to as China's public medical institutions) terminals and China's urban retail pharmacy terminals, in 2018 Siddinafi, Tadafi, Vandina non-total sales of more than 3 billion yuan, 2019 three major mainstream ED products continue to exert power, total sales exceeded 3.3 billion yuan, a total growth rate of more than 8%In terms of sub-species, Siddina is still the "sales champion", with end-sales of more than 2.3 billion yuan in retail pharmacies in China's cities in 2019, with a total growth rate of about 7% for the entire varietyThe combined growth rate of MrTadarafi is the highest, at more than 11%, in China's public medical facilities, which are ranked higher than in Thesitna, and the second round of national harvesting, which began in April, is expected to continue to be released in 2020Vandina non-overall sales are not outstanding, but the growth rate in 2019 reached 10%, the potential is still not to be underestimated, the product is currently the main focus of retail pharmacies, retail pharmacy terminals in China's urban pharmacies are also more than 30 million yuan level of varietiesThick thin hair, Baiyunshan summit called Wang table 1: China's urban retail pharmacy chemical drugs other urology system drug brand ranking TOP5 (units: billion yuan) Source: Minnet China's urban retail pharmacy pattern retail pharmacy is the main market for ED products, from the brand point of view, from 2018 to more than 1 billion brands rose to 2, 2019 Baiyunshan Pharmaceutical Factory finally dropped Pfizer, on the throneFigure 4: The market share of the non-TOP3 companies in Siddina Source: Minnet China's urban retail pharmacy pattern Pfizer's Wan ai is the founder of ED-type drugs, sales have been rising steadily since it was approved for market in the United States in 1998, and sales have been rising steadily since 2000, but with patents expiring, genericdrugs are flocking to the world, the product's global sales began to decline, leaving only $497 million in 2019In the domestic market, Pfizer's strongest rival, Baiyunshan Jingo, was first approved for listing in 2014, all the way to the thorns, market share gradually increased, in 2019 successfully reached the top of the list, becoming the leader of the variety At Minnet China's urban retail pharmacy terminal, The sales growth rate of Jingo in Baiyunshan in 2016-2019 was 40.04%, 42.78%, 10.92%, 12.91%, which has passed the 1 billion mark in 2018 and increased to 1.14 billion yuan in 2019 Baiyunshan mentioned in its 2019 annual report that the main reason for the year-on-year increase in sales of sildenafil is that the company continues to develop customers and promote sales growth with good sales channels Figure 5: Sidina non-rated enterprise situation Source: Minnet consistency evaluation database January 2020, Baiyunshan became the first non-evaluated enterprise in Xidina, Jiangsu Yabang Epson Pharmaceuticals supplementary application was also approved in April 2020 At present, ED-class mainstream drugs only headalafi entered the national collection, there is no relevant policy provisions in the drugstore sales of generic drugs must be evaluated, but as a best-selling brand, early completion of the layout, can also further improve consumer confidence A new generation of ED-type drugs will soon be introduced, the first imitation of the battle with The sea Cisco into a large heat table 2: 2018 to date in the review of THE ED-type drug market application source: Minnet MED China Drug Review Database 2.0 meters internal network data show that 2018 so far ed-type drug in review of the application involving 46 acceptance numbers, mainly around avanano- tablets, sildenafil non-tablets, he non-Dara three products Avanade is a highly selective PDE5 inhibitor for oral quick-acting, used in ED, originally developed by Japan's Tianbian Mitsubishi Pharmaceutical Co., Ltd authorized vivus Corporation of the United States, in April 2012 approved by the FDA to list, is currently listed in the United States, Germany, France, Italy and other countries, has not been imported or imitation in the country Clinical data show that avanaf can perform in the shortest time (15 minutes) compared to other PDE5 inhibitors, significantly faster than tadalafi, Sildinaf, Valdinafi, and Avanaf has higher selectivity to PDE1 and PDE6, with smaller adverse reactions than several other types of PDE5 inhibitors Sichuan Haicisco Pharmaceuticals and Shanghai Huilun Jiangsu Pharmaceuticals 3 types of imitation listing applications in August and September 2019, respectively, won the CDE, from the time point of view, Sea Cisco has a better advantage Guangdong Dongsun Pharmaceutical sand pharmaceutical industry and Guangzhou Long San Pharmaceutical sein in The dinafi, Hedarafi have a layout East Sunshine's Tadalafi tablets were awarded CDE in July 2018 and Siddina's non-contractor date is May 2019, and he is expected to be the first to be approved by the company as the first urological drug to be approved and treated as a result The above two products are also Guangzhou Long San Pharmaceutical san pharmaceutical in the field of urinary system drugs in the field of new breakthroughs, Sidafi, Tadalafi have a acceptance number in 2018 to obtain CDE contractor The impact of imported generic drugs on the domestic market is also not to be ignored, in the first batch of national collection alliance expansion stage, through the consistency evaluation to obtain "tickets" of Sanders (Reshuvastatin calcium tablets), Dr Reddy Laboratory of India (O nitrogen flat tablets) successfully won the bid, showing that the import of generic drugs further eat into the domestic generic drug market "desire" Alabindo Pharmaceuticals' sildenafil sildenafil non-tablets, Hainan Mei-Yu Pharmaceutical Technology's Hedaranon tablets are imported 5.2 listing applications, he has now entered the second round of national collection, and Siddinafi will be included in the future collection, if the time Alabindo Pharmaceuticals sildencyaric non-tablets approved imports, will become another strong domestic pharmaceutical enterprises? Pending market validation Source: NMPA official website, Minnet database review data statistics as of July 28, 2020, if there is any error, please point out
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.